Anticoagulation Forum/LinkedIn
                         
                                                                  Sep 13, 2025, 13:36 
                                
                                Emerging Evidence on Long-Term Oral Anticoagulation After Provoked VTE: Insights from the HI-PRO Trial
Anticoagulation Forum shared on LinkedIn.
“Join us for our free October webinar: Emerging Evidence: Long-term oral anticoagulation following provoked VTE? A focus on the HI-PRO Trial
Tuesday, October 7, 2025 | 12:00 PM ET
Join us as expert faculty review findings from the recent HI-PRO Trial on the use of apixaban for extended treatment of provoked venous thromboembolism (VTE).
What you’ll learn:
- Key insights from trial design and results
 - Clinical implications for real-world practice
 - Patient selection considerations for extended therapy
 
- Faculty:
 
Arthur Allen, PharmD, CACP – SALT LAKE CITY VA HEALTH CARE SYSTEM
Margaret Fang, MD, MPH – University of California, San Francisco
Gregory Piazza, MD, MS – Brigham and Women’s Hospital”

Register today here.
Read more on Hemostasis Today.
- 
                    Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
 - 
                    Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
 - 
                    Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
 - 
                    Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
 - 
                    Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
 
- 
                    Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
 - 
                    Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
 - 
                    Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
 - 
                    Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
 - 
                    Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
 
- 
                    Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
 - 
                    Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
 - 
                    Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
 - 
                    Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
 - 
                    Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
 
- 
                    Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
 - 
                    Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
 - 
                    Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
 - 
                    Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
 - 
                    Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry
 
Nov 3, 2025, 09:13 
                        
                    Nov 3, 2025, 08:23 
                        
                    Nov 3, 2025, 07:10 
                        
                    Nov 3, 2025, 04:56 
                        
                    